Objective To investigate the application of intravenous iron in patients with abnormal uterine bleeding (AUD) and iron deficiency anemia (IDA) in gynecology, to establish the drug utilization evaluation (DUE) standard, and to comprehensively evaluate the rationality of the clinical application of intravenous iron by analytic hierarchy process (AHP), so as to provide reference for the rational use of intravenous iron in clinical practice.

Methods The medical records of patients with AUD and IDA from January to December 2022 in the First Affiliated Hospital of Anhui University of Science and Technology were collected, and the special rationality of the drug was evaluated from the aspects of indications, route and frequency of administration, daily dosage, solvent, combination medication, and contraindications of iron sucrose injection, and the DUE standard of the drug was formulated. AHP was used to analyze and evaluate 113 archived cases of intravenous iron in gynecology from January to December 2022.

Results A total of 113 patients were treated with iron sucrose injection, and the indications, route of administration, solvent, contraindications, and allergic reactions were reasonable. The main unreasonableness was that the frequency of administration was inappropriate, the daily dose was inappropriate, the combination was not appropriate, the total iron supplement was not up to standard, and there was no continuous drug monitoring after medication. The case scores 90~100, 70~<90 and 60~<70 were 6 (5.31%), 106 (93.81%) and 1  (0.88%), respectively.

Conclusion  Patients with AUD and IDA should pay attention to the dosage, total amount of iron supplementation, combined application of drugs and continuous medication monitoring after intravenous iron supplementation, so as to improve the rationality of their use.

1.Khafaga A, Goldstein SR. Abnormal uterine bleeding[J]. Obstet Gynecol Clin North Am, 2019, 46(4): 595-605. DOI: 10.1016/j.ogc.2019.07.001.

2.Hong W, Wang BY, Wu ZP, et al. Systematic retrospective analysis of 13 cases of uterine arteriovenous fistula: pathogeny, diagnosis,treatment and follow-up[J]. J Obstet Gynaecol Res, 2020, 46(7): 1117-1127. DOI: 10.1111/jog.14264.

3.Owaidah T, Al-Numair N, Al-Suliman A, et al. Iron deficiency and iron deficiency anemia are common epidemiological conditions in Saudi Arabia: report of the national epidemiological survey[J]. Anemia, 2020, 2020: 6642568. DOI: 10.1155/2020/6642568.

4.吴颖其, 姜玲, 张圣雨, 等. 我院蔗糖铁注射液药物利用评价标准的建立及应用[J]. 中国药房, 2017, 28(2): 270-273．[Wu YQ, Jiang L, Zhang SY, et al. Establishment and application of DUE standard for iron sucrose injection in our hospital[J]. China Pharmacy, 2017, 28(2): 270-273.] DOI: 10.6039/j.issn.1001-0408.2017.02.35.

5.罗国庆, 蒋巧俐, 余莹. 蔗糖铁注射液在产科的应用调查[J]. 医药导报, 2018, 37(9): 1127-1129. [Luo GQ, Jiang QL, Yu Y. Investigation on the application of iron sucrose injection in obstetrics[J]. Herald of Medicine, 2018, 37(9): 1127-1129.] DOI: 10.3870/j.issn.1004-0781. 2018.09.023.

6.张鹏程, 宋佳伟, 王雪倩, 等. 达格列净应用合理性评价[J]. 中国现代应用药学, 2023, 40(2): 269-273. [Zhang PC, Song JW, Wang XQ, et al. Evaluation of application rationality of dapagliflozin[J]. Chinese Journal of Modern Applied Pharmacy, 2023, 40(2): 269-273.] DOI: 10.13748/j.cnki.issn1007-7693.2023.02.019.

7.狄文. 静脉铁剂在妇科肿瘤围手术期贫血治疗中的应用[J]. 临床药物治疗杂志, 2023, 21(1): 44-48. [Di W. Application of intravenous iron in the treatment of perioperative anemia in gynecological oncology [J]. Clinical Medication Journal, 2023, 21(1): 44-48.] DOI: 10. 3969/j. issn. 1672-3384. 2023. 01. 009.

8.中华医学会血液学分会红细胞疾病（贫血）学组. 静脉铁剂应用中国专家共识（2019年版）[J]. 中华血液学杂志, 2019, 40(5): 358-362. DOI: 10.3760/cma.j.issn.0253-2727.2019.05.002.

9.吴德沛, 宣建伟. 蔗糖铁治疗缺铁性贫血的真实世界研究[J]. 临床药物治疗杂志, 2022, 20(7): 32-39. [Wu DP, Xuan JW. Iron sucrose in IDA patients: a real-world study[J]. Clinical Medication Journal, 2022, 20(7): 32-39.] DOI: 10. 3969/j. issn. 1672-3384. 2022. 07. 006.

10.黄蕾, 刘丽文, 凌艳芝, 等. 异麦芽糖酐铁治疗异常子宫出血相关缺铁性贫血的疗效及安全性研究[J]. 实用临床医药杂志, 2023, 27(18): 123-126. [Huang L, Liu LW, Ling YZ, et al. Efficacy and safety of ferric derisomaltose in the treatment of iron deficiency anemia caused by abnormal uterine bleeding[J]. Journal of Clinical Medicine in Practice, 2023, 27(18): 123-126.] DOI: 10.7619 /jcmp.20231602.

11.潘振峰, 王兴东, 李晓敏, 等. 慢性肾脏病患者铁剂的利用评价及安全性分析[J]中国医院药学杂志, 2022, 42(21): 2264-2266. [Pan ZF, Wang XD, Li XM, et al. Application evaluation and safety analysis of iron agent used in patients with chronic kidney diease[J]. Chinese Journal of Hospital Pharmacy, 2022, 42(21): 2264-2266.] DOI: 10.13286/j.1001-5213.2022.21.12.

12.张瑞, 韩明锋, 李龙海, 等. 临床药师对肿瘤科应用蔗糖铁注射液115例评价分析[J]. 安徽医药, 2021, 25(7): 1473-1476. [Zhang R, Han MF, Li LH, et al. Evaluation and analysis of 115 cases of application of sucrose iron injection by clinical pharmacists in oncology department[J]. Anhui Medical and Pharmaceutical Journal, 2021, 25(7): 1473-1476.] DOI: 10.3969/j.issn.1009-6469.2021.07.049.

13.朱玲春. 规范口服铁剂对合并高危出血因素妊娠期缺铁性贫血产妇产后出血率的影响[J]. 中国妇幼保健, 2021, 36(13): 2963-2966.  [Zhu LC. Effect of standardized oral iron supplementation on postpartum hemorrhage rate in pregnant women with iron deficiency anemia in pregnancy complicated with high-risk bleeding factors[J]. Maternal and Child Health Care of China, 2021, 36(13): 2963-2966.] DOI: 10.19829/j.zgfybj.issn.1001-4411.2021.13.012.

14.黄可佳, 邵宁, 姜鑫鑫, 等. 蔗糖铁合理使用评价体系的构建与实践[J]. 重庆医学, 2022, 51(9): 1564-1568, 1577. [Huang KJ, Shao N, Jiang XX, et al. Construction and practice of evaluation system for rational use of iron sucrose[J]. Chongqing Medicine, 2022, 51(9): 1564-1568, 1577.] DOI: 10.3969/j.issn.1671-8348.2022.09.026.

15.吴玉. 蔗糖铁注射液治疗对异常子宫出血相关性贫血患者临床疗效、红细胞指标及铁代谢指标的影响[J]. 中国药物经济学, 2023, 18(10): 101-104. [Wu Y. Effect of sucrose iron injection on clinical efficacy, red blood cell index and iron metabolism index of patients with anemia associated with abnormal uterine bleeding[J]. China Journal of Pharmaceutical Economics, 2023, 18(10): 101-104.] DOI: 10.12010/j.issn.1673-5846.2023.10.023.

16.贝世芳, 戚雪勇, 王娜,等. 284 例静脉用铁剂不良反应的调查研究和报告质量分析[J]. 现代药物与临床, 2021, 36(11): 2413-2417. [Bei SF, Qi XY, Wang N, et al. Investigation and quality analysis of intravenous iron adverse reactions of 284 cases[J]. Drugs & Clinic, 2021, 36(11): 2413-2417.] DOI: 10.7501/j.issn.1674-5515.2021.11.038.

17.何青青, 田娜妮, 姚杨, 等. 基于AHM-Topsis 法的骨科围手术期蔗糖铁注射液合理性评价[J]. 实用药物与临床, 2022, 25(12): 1098-1102. [He QQ, Tian NN, Yao Y, et al. Evaluation of rationality of iron sucrose injection in orthopedic perioperative period based on AHM-Topsis[J]. Practical Pharmacy And Clinical Remedies, 2022, 25(12): 1098-1102. DOI: 10.14053/j.cnki.ppcr.202212009.

18.杨佳, 李根, 刘雪梅, 等. PDCA循环用于蔗糖铁合理使用评价体系实践与效果[J]. 中国药业, 2018, 27(9): 92-95. [Yang J, Li G, Liu XM, et al. Application and effect of PDCA cycle in the evaluation system of rational use of iron sucrose injection[J]. China Pharmaceuticals, 2018, 27(9): 92-95.] DOI: 10.3969/j.issn.1006- 4931.2018.09.030.

19.朱彤, 刘艳, 吴献,等.静脉铁剂的临床应用现状及其类似物治疗特点[J]. 中国临床药学杂志, 2023, 32(5): 394-400. [Zhu T, Liu Y, Wu X, et al. The current status of the clinical application of intravenous iron and the therapeutic characteristics of its analogues[J]. Chinese Journal of Clincal Pharmacy, 2023, 32(5): 394-400.] DOI: 10.19577/j.1007-4406.2023.05.015.

20.刘小欢, 唐怡, 王清坪. 2018-2019 年西部战区总医院住院肾性贫血患者蔗糖铁注射液的使用合理性分析[J]. 现代药物与临床, 2019, 34(11): 3447-3451. [Liu XH, Tang Y, Wang QP. Analysis on reasonable use of Iron Sucrose Injection for renal anemia in hospitalized patients in The General Hospital of Western Theater Command from 2018 to 2019[J]. Drugs & Clinic, 2019, 34(11): 3447-3451.] DOI: 10.7501/j.issn.1674-5515.2019.11.054.